Skip to content

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

The Value and Potential Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Non-Hodgkin Lymphomas.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03000738
Enrollment
100
Registered
2016-12-22
Start date
2016-12-31
Completion date
2019-12-31
Last updated
2017-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma, Lymphoma,Non-Hodgkin, Peripheral T-Cell Lymphoma

Keywords

CD16- monocyte/CD16+ monocyte ratio, CytoDiff flow cytometric system, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma, prognosis

Brief summary

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.

Detailed description

The investigators plan to prospectively involve 100 non-hodgekin lymphoma patients, including 50 diffuse large B cell lymphomas and 50 peripheral T cell lymphomas without previous treatment from Peking Union Medical College Hospital. The following parameters were collected: age, sex, subtype, Eastern Cooperative Oncology Group (ECOG) performance status (PS), Ann Arbor stage (I-IV), presence of B symptoms, number and type of involved sites, prognostic index including International Prognostic Index (IPI) for DLBCLand PIT for PTCL based on medical record review. All patients would have regular treatment and follow up in PUMCH. During the follow up, treatment response was evaluated by enhanced computed tomography or PET-CT. The peripheral blood would be collected. The Cytodiff flow cytometric technique would be used to test 16 leukocyte subpopulations from peripheral blood at the time of diagnosis, interim of treatment, end of treatment, 1 year follow-up, 1.5 year of follow-up, 2 year of follow up, 3 year of follow-up and disease progression. Progression-free survival (PFS) and overall survival (OS) would be estimated using the Kaplan-Meier method and two-tailed log-rank test.The Cox proportional hazards model would evaluate prognostic factors for OS and PFS. Specificity, sensitivity and cut-off would be established using time-dependent receiver operating characteristic (ROC) curve analysis. Area under curve (AUC) values \>0.7 indicate that the parameter can be used for diagnosis, with values \>0.9 indicating high clinical accuracy.

Interventions

None listed

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. pathologically confirmed diffuse large B cell lymphoma (DLBCL nos, PCNSL, ALK+ DLBCL, DLBCL/BL) or peripheral T cell lymphoma (AITL, ALCL, PTCL nos, NK/T nasal type, EATL, HSTL) 2. no treatment before 3. hCG(-) 4. 18 years old to 80 years old

Exclusion criteria

1. other tumors 2. severe infections

Design outcomes

Primary

MeasureTime frame
overall survival3 years

Secondary

MeasureTime frame
progression free survival3 years

Contacts

Primary ContactWei Zhang
vv1223@vip.sina.com+86-010-69151235
Backup ContactXiao Han
xiaoer020@vip.sina.com+86 18618191308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026